Skip Navigation

COVID-19: We are vaccinating patients ages 12+. Learn more:

Vaccines, Boosters & Additional Doses | Testing | Patient Care | Visitor Guidelines | Coronavirus | Self-Checker | Email Alerts


Philips Respironics issued a recall for some CPAP and BiLevel PAP devices and mechanical ventilators. Learn more.

Frontotemporal Dementia (FTD) and Young-Onset Dementias Clinic

Clarity. Comfort. Guidance. Care. Male nurse assisting senior man in nursing home

Frontotemporal Dementia (FTD) and Young-Onset Dementias Clinic

The Frontotemporal Dementia and Young-Onset Dementias Clinic is dedicated to the care of individuals who suffer from frontotemporal dementias (FTD), Creutzfeldt-Jakob Disease (CJD), and those who are under 65 years of age with any type of dementia. Located in the Division of Geriatric Psychiatry and Neuropsychiatry, the clinic serves Maryland, neighboring states, and the District of Columbia. Our services are also available for consultations and clinical care for patients from anywhere in the United States or abroad.

Conditions We Treat

  • Frontotemporal Dementias

    Frontotemporal dementia (FTD), a common cause of dementia, is a group of disorders that occur when nerve cells in the frontal and temporal lobes of the brain are lost. This causes the lobes to shrink. FTD can affect behavior, personality, language, and movement.

  • Young-Onset Dementias

    When Alzheimer disease occurs in someone under age 65, it is known as early-onset (or younger-onset) Alzheimer disease.

  • Creutzfeldt-Jakob and Other Prion Diseases

    The most common form of prion disease that affects humans is Creutzfeldt-Jakob disease (CJD). Prion diseases are rare. About 300 cases are reported each year in the U.S.


Comprehensive Care and Support

We offer a number of medical services relating to the evaluation and care of individuals suffering from these dementias: diagnostic evaluations, illness education,  medication and non-medication treatments, and, in specific circumstances, admission to a specialized hospital unit. The clinic is conducting many research projects, including clinical trials and studies of day-to-day care, as well as epidemiologic, neuropsychiatric, neuropathological, and genetic investigations.

Our commitment to the sufferers of young-onset dementias and their families also includes a range of support services such as:

  • Management of symptoms commonly associated with dementia
  • A support group for anyone providing care to people with FTD
  • Dementia-care education and planning
  • Social work services
  • Liaison with respite care and residential care providers
  • Guidance with issues pertaining to dependent children
  • Home visits (in certain circumstances)
  • Conducting research to improve management of these diseases
  • Patient Information

    Details on making an appointment and preparing for your visit

  • Research

    Research covers a range of topics relating to the mechanisms and manifestations of the diseases, the costs and burdens of caring for sufferers, the quality of care and services, and the identification and development of effective treatments.


Contact Us


The Johns Hopkins FTD  and Young-Onset Dementias Clinic
Division of Geriatric Psychiatry and Neuropsychiatry
600 N. Wolfe Street, Suite 235
Baltimore, Maryland 21287

Phone: 410-955-5147
Fax: 410-502-4133

Clinic Leadership

Director:  Chiadi U. Onyike, M.D., M.H.S.
Clinic Nurse/Coordinator:  Mary Anne Wylie, M.S., R.N., A.P.N.
Clinic Nurse: Rebecca Rye, R.N.
Front Desk: Myra Franklin


Meet Dr. Onyike 

Not just a condition for the elderly: early-onset Alzheimer’s

Dr Onyike discusses how this affects the treatment of early-onset Alzheimer’s patients, and gives details about the opportunities that studying this condition could present. This interview was recorded at the 2017 Alzheimer’s Association International Conference (AAIC) held in London, UK.

Different treatments for different phenotypes?

Dr Onyike speaks to us about how identifying the vulnerabilities of susceptible regions of the brain may further our comprehension, and could lead to new, targeted treatments. This interview was recorded at the 2017 Alzheimer’s Association International Conference (AAIC) held in London, UK.

back to top button